Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q4 2014 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$3.33M$3.33Mderived−60.4% vs Q4 2013 Net Income-$24.63M-$24.63MderivedN/M vs Q4 2013 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived-$3,918,686N/M Operating Incomederived-$21,901,863N/M Operating Cash Flowderived$1,975,942−59.7% Free Cash Flowderived$1,485,508N/M Margins · derivedGross margin-117.6%−78.4 pt vs Q4 2013
Operating margin-657.5%−560.5 pt vs Q4 2013
Net margin-739.4%−615.4 pt vs Q4 2013
ended Dec 31, 2014 · filed Mar 30, 2015 · 89 d after period end